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Abstract
Head and Neck Squamous Cell Carcinoma (HNSCC) encompasses malignancies that arise in the mucosa of the upper
aerodigestive tract. Recent high throughput DNA sequencing revealed HNSCC genes mutations that contribute to several
cancer cell characteristics, including dysregulation of cell proliferation and death, intracellular proinflammatory signaling,
and autophagy. The PYRIN-domain containing NLR (Nucleotide-binding domain, Leucine rich Repeats – containing) proteins
have recently emerged as pivotal modulators of cell death, autophagy, inflammation, and metabolism. Their close
physiologic association with cancer development prompted us to determine whether mutations within the NLRP (PYRIN-
containing NLR) gene family were associated with HNSCC genome instability and their clinicopathologic correlations.
Catastrophic mutational events underlie cancer cell genome instability and mark a point-of-no-return in cancer cell
development and generation of heterogeneity. The mutation profiles of 62 patients with primary conventional type HNSCC
excluding other histologic variants were analyzed. Associations were tested using Fisher’s Exact test or Mann-Whitney U
test. Mutations in NLRP were associated with elevated genome instability as characterized by higher mutation rates.
Clinically, NLRP mutations were more frequently found in HNSCC arising in the floor of mouth (50.0%) in comparison with
HNSCC at other head and neck locations (14.8%). These mutations were clustered at the leucine rich repeats region of NLRP
proteins, and affected NLRP genes were mostly localized at chromosomes 11p15.4 and 19q13.42-19q13.43. Twenty novel
NLRP mutations were identified in HNSCC, and mutations in this group of genes were correlated with increased cancer cell
genome mutation rates, and such features could be a potential molecular biomarker of HNSCC genome instability.
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Introduction
Recent technological advances in whole exome sequencing at
much greater depths provide us with an unparalleled opportunity
to interrogate the human cancer genome for mutational profiles.
Studies on the evolutionary history of cancer genomes reveal that
catastrophic mutational events (also referred to as ‘‘kataegis’’, a
Greek word meaning thunderstorm or shower), which are
characterized by rapid accumulation of point mutations at
clustered regions, may mark a ‘‘point-of-no-return’’ during cancer
development by giving rise to subclones of cancer cells [1,2].
Genome instability exemplified by kataegis and chromothripsis
represents a hallmark of cancer [3].
Head and Neck Squamous Cell Carcinoma (HNSCC) encom-
passes malignancies that arise in the mucosa of the upper
aerodigestive tract, accounting for 300,000 annual deaths and
ranking 6th among the most common human cancers [4]. Due to
the characteristic anatomic location, the upper aerodigestive
pathway, especially the oral cavity, is constantly exposed to
environmental factors, many of which possess potent carcinogenic
capacity. Indeed, the geographic variation of HNSCC incidence
corresponds well with the exposure to risk factors including
tobacco use and human papilloma virus (HPV) infection [5]. The
unique environmental etiologic factors in HNSCC development
suggest the functional significance of genes involved in host-
environment and/or host-pathogen interactions. Novel mutations
in genes regulating squamous epithelial differentiation are unveiled
in recent endeavors to map HNSCC mutational landscape [6,7].
However, the genetic signatures that may reflect the overall
genome instability in HNSCC are yet to be determined. This
study aims to explore the significance of mutations in a group of
genes modulating host-environment interactions and their clini-
copathologic correlations.
Emerging evidence place a novel gene family at the forefront of
host-environment interactions. NLR (nucleotide-binding, lots of
leucine-rich repeats containing) gene family (initially coined as
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CATERPILLER, also known as NOD and NALP) is characterized
by a central nucleotide-binding domain, a C-terminal leucine rich
repeats (LRR) domain, and an N-terminal effector domain. The
N-terminus could be CARD, PYRIN, BIR, AD or X domain,
which shows certain homology with CARD or PYRIN yet cannot
be categorized into either [8]. By engaging with the formation of
distinct protein complexes, NLR proteins play central roles in
modulating host responses to both PAMPs (pathogen-associated
molecular patterns) and DAMPs (damage-associated molecular
patterns) [9,10].
A variety of NLR-mediated signaling pathways convey metic-
ulous regulatory mechanisms in cell death [11], inflammation
[9,10,12], autophagy [13–16], and more recently carcinogenesis
[17–24]. Among the NLR family, a subgroup of NLRs harboring
an N-terminal PYRIN domain have been implicated in malig-
nancies arising in the lower digestive tract. Indeed, genetic
deficiency in Nlrp3 results in increased colitis-associated colon
cancer [19,25]. NLRP6 controls colonic microbial ecology and
colorectal epithelial cells renewal; and its deficiency results in
increased colitis and colorectal cancer [21–23]. NLRP7 variants
are involved in post-molar choriocarcinoma, and a germline
mutation of NLRP2 is associated with a proliferation disorder
known as Beckwith-Wiedemann syndrome [26,27].
A significant portion of HNSCC is comprised of cancer of the
oral cavity, which is not only directly exposed to a variety of
PAMPs and DAMPs, but also constantly inhabited by a
microbiota composed of more than 700 bacterial species [28].
Alteration of oral microbiota as seen in those with chronic adult
periodontitis or poor oral hygiene has been correlated with the
development of several types of cancer [29,30]. Given the
significance of NLR proteins in host inflammatory responses,
autophagy, normal epithelial renewal, and emerging roles in
maintaining microbiota homeostasis [13,18,21–23], their deficien-
cy may change host responses to environmental insults and
adjuvant therapeutic agents. However, their specific functions in
modulating cancer cell development require further investigations.
In this study, we characterize the mutational profiles of 10 NLRP
genes in 62 primary conventional type HNSCC tumors, and
investigate the significance of these mutations in overall cancer
genome instability and their correlations with the clinicopathologic
characteristics of HNSCC patients.
Results
Identification of NLRP mutations in HNSCC
A solution-phase hybrid capture and whole exome sequencing
with a mean of 150-fold sequence coverage at targeted exonic
regions were performed on HNSCC specimens as previously
reported [6]. Among all sequenced specimens in the previous
study [6], several histologic variants of primary or recurrent
HNSCC existed including conventional type SCC (squamous cell
carcinoma), basaloid SCC, papillary SCC, spindle cell carcinoma,
adenosquamous cell carcinoma, and hybrid verrucous SCC. The
latest World Health Organization classification of head and neck
tumors (2005) presents a general consensus that these variants may
display varied clinical courses and prognoses compared to
conventional type SCC. For instance, basaloid squamous cell
carcinoma and adenosquamous cell carcinoma are considered to
behave more aggressively with early metastasis; papillary squa-
mous cell carcinoma and verrucous carcinoma are slow-growing
tumors and may show better prognosis than conventional
HNSCC. In order to a perform analyses in a relatively more
homogenous population, we restricted our study to 62 patients
with primary conventional type HNSCC.
Non-silent mutations were detected in 10 of 14 human NLRP
genes (NLRP1-14). The whole group of the NLRP genes was affected
except for NLRP6, NLRP7, NLRP9, and NLRP13. Non-silent NLRP
mutations were present in tumors from 13 patients (Table 1).
Mutations in more than 1 NLRP genes were identified in 3 tumors.
Despite the unknown genetic or environmental predisposition for
cancer development at the floor of mouth (FOM), this site is
recognized as being a high risk site for HNSCC [31]. Hence, we also
reviewed the NLRP mutational profiles in 8 FOM HNSCC tumors;
four tumors harbored NLRP mutations. In addition to our study of
62 conventional HNSCC, NLRPmutations have also been reported
in HNSCC in an independent whole exome sequencing study of
HNSCC [7] and in the Catalog of Somatic Mutations in Cancer
(COSMIC) database. NLRP mutations most frequently occur at the
C-terminus followed by the NBD domain (Figure 1).
NLRP mutations were associated with increased cancer
genome instability
Catastrophic mutational events reflect a high degree of genome
instability, which is one of the hallmarks of cancer. Thus we
evaluated whether mutations in NLRP genes reflected the overall
cancer genome instability. Tumors without NLRP mutations
Table 1. Identification of NLRP mutations in primary HNSCC.
Chromosome Location NLRP Genes
19q13.42-19q13.43 NLRP2, NLRP4, NLRP5, NLRP8, NLRP11, NLRP12
11p15.4 NLRP10, NLRP14
17p13.2 NLRP1
1q44 NLRP3
Novel mutations were identified in 10 NLRP genes in HNSCC. Most mutations
were involving chromosomal locations 11p15.4 and 19q13.42-19q13.43.
doi:10.1371/journal.pone.0085619.t001
Figure 1. Identification of NLRP mutations in FOM HNSCC.
Mutations in four NLRP genes were identified in FOM HNSCC patients.
Black triangles indicate novel mutations identified in this study. Gray
triangles represent reported mutations in the Catalogue of Somatic
Mutations in Cancer (COSMIC) database.
doi:10.1371/journal.pone.0085619.g001
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harbor an average of 68 missense mutations, while those with
NLRP mutations demonstrate as twice as many missense mutations
across their exomes (P= 0.015) (Figure 2A). In agreement with
previous findings, two recent large-scale sequencing studies also
identified frequent mutations of TP53 in HNSCC [6,7], which
may drive kataegis in a fraction of the tumors. However, the
missense mutation rate in tumors without TP53 mutations was
comparable to that in those with TP53 mutations (Figure 2B).
Despite of the similar size between the human gene family of TLR,
which is comprised of 10 genes (TLR1-10), and pyrin-containing
NLRs, TLR gene mutations were only identified in 7 tumors. Both
selected gene members of the TLR or NLRP families, which were
mutated in our cohort of 62 tumors, and total members of both
families were compared in light of the length of coding regions.
Our analysis showed that the coding regions of both groups of
genes were similar (Figure S2). Thus, we employed the TLR gene
family as another control for our gene mutation analysis. The
missense mutations in tumors with TLR mutations were higher
than those without TLR mutations with a marginal P value
(P= 0.041) (Figure 2C). In addition, HNSCC with NLRP
mutations displayed generalized elevated genome instability
exemplified by general mutation rate (P = 0.0095), silent mutation
rate (P = 0.016), and non-silent mutation rate (P = 0.0134)
(Figure 2D). HNSCC with TP53 mutations also demonstrated
Figure 2. Mutation rates comparisons. (A) Numbers of missense and nonsense mutations were compared between tumors with or without NLRP
mutations. (B) Numbers of missense and nonsense mutations were compared between tumors with or without TP53 mutations. (C) Numbers of
missense and nonsense mutations were compared between tumors with or without TLR genes mutations. (D) Mutation rates [shown as mutations
per million base (MB) pairs] were compared between tumors with or without NLRP mutations. (E) Mutation rates [shown as mutations per million
base (MB) pairs] were compared between tumors with or without TP53mutations. (F) Mutation rates [shown as mutations per million base (MB) pairs]
were compared between tumors with or without TLR genes mutations. P value less than 0.05 was considered significant.
doi:10.1371/journal.pone.0085619.g002
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Table 2. Demographic Profile of Study Subjects with Primary Conventional HNSCC (PC-SCC).
All PC-SCC Cases
PC-SCC Cases with NLRP
mutation
PC-SCC Cases without NLRP
mutation
n=62 n=13 n=49 P*
Gender
Male 47 75.8% 8 61.5% 39 79.6% 0.27I
Female 15 24.2% 5 38.5% 10 20.4%
Age, years
Average (Range) 57 (33–76) 59 (39–75) 56 (33–76) 0.301
Cigarette Pack-Years
Never smoker 10 16.1% 3 23.1% 7 14.3% 0.62I
1–49 py 38 61.3% 8 61.5% 30 61.2%
$50 py 14 22.6% 2 15.4% 12 24.5%
Alcohol Quantity{
Never drinker 12 19.4% 4 30.8% 8 16.3% 0.13I
1–4 7 11.3% 3 23.1% 4 8.2%
$5 41 66.1% 6 46.2% 35 71.4%
Unknown 2 3.2% 0 0.0% 2 4.1%
Tumor Site
Oral Cavity 31 50.0% 8 61.5% 23 46.9% 0.98I
Oropharynx 10 16.1% 2 15.4% 8 16.3%
Hypopharynx 8 12.9% 1 7.7% 7 14.3%
Larynx 11 17.7% 2 15.4% 9 18.4%
Sinonasal 2 3.2% 0 0.0% 2 4.1%
Disease Stage
I 0 0.0% 0 0.0% 0 0.0% 0.87I
II 5 1.4% 1 7.7% 4 8.2%
III 12 3.4% 3 23.1% 9 18.4%
IV 45 12.7% 9 69.2% 36 73.5%
Histologic Grade
Well Differentiated 1 1.6% 0 0.0% 1 2.0% 0.80I
Moderately Differentiated 39 62.9% 9 69.2% 30 61.2%
Poorly Differentiated 22 35.5% 4 30.8% 18 36.7%
HPV Status
Positive 10 16.1% 1 7.7% 9 18.4% 0.67I
Negative 52 83.9% 12 92.3% 40 81.6%
Treatment
RT Only 11 17.7% 4 30.8% 7 14.3% 0.29I
CRT 38 61.3% 6 46.2% 32 65.3%
No CRT 13 21.0% 3 23.1% 10 20.4%
Unknown 0 0.0% 0 0.0% 0 0.0%
Vital Status
Alive 29 46.8% 6 46.2% 23 46.9% 1.00I
Dead 33 53.2% 7 53.8% 26 53.1%
5-year overall survival, months
Median (Range) 34.3 (2.0–60.0) 22.1 (2.4–58.0) 37.9 (4.6–60.0) 0.58"
Disease Progression
No disease progression 22 35.5% 6 46.2% 16 32.7% 0.27I
Local/Regional Recurrence 12 19.4% 0 0.0% 12 24.5%
Second Primary 2 3.2% 0 0.0% 2 4.1%
Distant Metastasis 8 12.9% 2 15.4% 6 12.2%
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higher general mutation rate and non-silent mutation rates
(P = 0.041 and P= 0.038, respectively) yet similar silent mutation
rates (Figure 2E). Similar to tumors with TP53 mutations, the
tumors with TLR mutations more commonly demonstrated higher
general mutation rates and non-silent mutation rates (P = 0.048
and P= 0.030, respectively) (Figure 2F). However the silent
mutation rates between tumors with or without TLR genes
mutations were comparable (Figure 2F).
Demographic information of patients involved in the
study
Primary conventional HNSCC has a strong predilection for
males; however, this gender predilection appeared to be mitigated
in patients harboring NLRPmutations, as the representation among
females with HNSCC increased from 24% of all included patients in
this study to almost 40% among those patients with NLRP
mutations, although this difference was not statistically significant
(Table 2). Neither tobacco nor alcohol use was associated with these
mutations. Most examined clinical parameters, such as disease
stage, histologic grade, human papilloma virus (HPV) status, 5-year
survival and disease progression, did not differ between the patients
with and without NLRP mutations (Table 2).
NLRP mutations were associated with HNSCC arising in
the floor of mouth (FOM)
Floor of mouth is an unequivocal high risk site for HNSCC
according to the recent WHO Classification of Head and Neck
Tumours (2005). In a comprehensive study of 3,360 specimens,
leukoplakia at floor of mouth has the highest incidence showing
epithelial dysplasia and carcinoma compared to leukoplakic lesions
at all other anatomic locations in the oral cavity [32]. However,
the genetic alterations that may occur in this region leading to
development of tumors at this anatomical site remain poorly
understood. We assessed the correlation between NLRP mutations
and tumor site in 62 patients. NLRP mutations were more
common in HNSCC arising in the FOM (P=0.079 in comparison
with HNSCC in other non-FOM oral cavity locations, P= 0.034
in comparison with HNSCC in other non-FOM head and neck
locations) (Table 3). To determine whether the clustering of NLRP
mutations in this site was because of elevated genome instability of
FOM HNSCC compared to HNSCC at other sites, we evaluated
missense mutation, nonsense mutation, and mutation rates. No
significant differences were identified between FOM and non-
FOM groups (Figure 3A, 3B), indicating that the higher rate of
NLRP mutations in FOM HNSCC was not a nonspecific reflection
of an overall higher mutation rate at this anatomic site. In order to
further substantiate the specificity of this association, we also
explored whether mutations in TP53 or TLR genes were clustered
in FOM HNSCC. Although mutations of TP53 or TLR genes
were seen in a group of patients with higher general mutation rate
and non-silent mutation rate, these mutations were not associated
with HNSCC arising in FOM (Tables S1 and S2).
Identification of factors affecting the survival of patients
with primary conventional type HNSCC
Tumors harboring NLRP mutations had significantly increased
general mutation rate and missense mutations; however, the
presence of these mutations was not associated with patients
overall survival (Figure 4A). Although TP53 mutations were
present in 67.7% of the total tumor specimens, these mutations did
not affect patient survival (Figure 4B). The presence of TLR
mutations had little prognostic value in patients survival
(Figure 4C). Among all factors tested, only HPV infection status
and tumor stage were associated with overall survival. In
agreement with previous literatures [33,34], patients with HPV-
positive tumors had improved survival (P = 0.094) (Figure 4D). In
fact, HPV-positive tumors demonstrated a significantly lower
missense mutations and general mutation rates (Figure S1A, S1B).
Despite the fact that the majority of the patients involved in this
study were at advanced stage (stage III and beyond), our analysis
showed low stage status positively impacted overall survival
(Figure 4E). However, tumor stage was not associated with
increased genome instability (Figure S1C, S1D). Neither age nor
Table 2. Cont.
All PC-SCC Cases
PC-SCC Cases with NLRP
mutation
PC-SCC Cases without NLRP
mutation
n=62 n=13 n=49 P*
Death without Recurrence 18 29.0% 5 38.5% 13 26.5%
5-year Progression Free Survival, months
Median (Range) 20.3 (2.0–60.0) 19.1 (2.4–58.0) 21.5 (4.6–60.0) 0.78"
Contingency tables were analyzed by Fisher’s exact test. Survival distributions were analyzed by Log Rank test.
Notes:
{Typical number of alcohol drinks in 2 week period, 1Mann-Whitney U test,
IFisher’s exact test,
"Log rank test,
*Comparing patients with or without mutations in NLRP genes.
doi:10.1371/journal.pone.0085619.t002
Table 3. Mutations in NLRP genes were more frequently
found in FOM HNSCC.
NLRP Mut. w/o NLRP mut. P value
FOM 4 4
Non-FOM 4 19 0.079
(all other OC locations)
FOM 4 4
Non-FOM 8 46 0.034
(all other H&N locations)
Contingency table comparisons were made by Fisher’s Exact test. P value of less
than 0.1 was considered significant.
doi:10.1371/journal.pone.0085619.t003
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adjuvant therapies such as chemotherapy or radiotherapy were
associated with patients survival (Figure 4F–G).
Discussion
NLRP proteins are evolutionarily and functionally conserved.
The NLR gene family was initially discovered through genomic
database mining based on structural homology [9]. By incorpo-
rating an N-terminal effector domain, a central nucleotide-binding
domain, and a variable number of LRR at the C-terminus, the 22
human NLR proteins are structurally similar to the plant R
protein, which conveys resistance to pathogens [8]. The pioneer-
ing research on NLR proteins primarily focused on their pivotal
roles in modulating inflammatory responses such as caspase-1
activation, MAPK, NF-kB, and mitochondria-based antiviral
signaling [9,10,13,35]. Several NLRs possess similar functions in
facilitating the assembly of a large multimeric protein complex,
coined as the inflammasome, to process pro-caspase-1 into its
mature form, which induces the maturation and secretion of IL-1b
and IL-18, in response to a variety of PAMPs and DAMPs [9].
Both HNSCC derived cell lines and invasive HNSCC tumor cells
produce proinflammatory cytokines including IL-1b, TNF-a, and
IL-6 [36,37]. In addition, elevated salivary IL-1b has been found
in oral squamous cell carcinoma patients [38]. Among the NLRP
proteins, NLRP1, 2, 3, and 12 participate in the formation and
activation of inflammasome [9], and mutations in these genes were
identified in HNSCC.
HNSCC is notorious for its heterogeneity and frequent
resistance to adjuvant therapies. In addition to the aforementioned
inflammatory pathways, NLR proteins have also been implicated
in the regulation of autophagy, which conveys resistance to a
variety of adjuvant therapeutic agents [39]. A NLR protein NOD2
induces autophagy in dendritic cells upon engagement with
muramyldipeptide [14]. NLRP4 associates with beclin1 to
negatively regulate autophagy [15]. NLRX1 modulates autophagy
by recruiting ATG12, ATG5, and ATG16L1 to a large
mitochondrial protein complex, through an intermediary partner
TUFM [13,16]. Inhibition of autophagy is proven an effective
strategy in sensitizing HNSCC cells to a number of adjuvant
therapeutic agents. The majority of the mutation of NLRP genes in
HNSCC are located at the C-terminal LRR domain. With the
roles of NLR proteins in modulating autophagy being unveiled, it
would be necessary to evaluate the function of these autophagy-
related NLRs in modulating cancer cell resistance to novel
adjuvant therapy.
One critical event that precedes the generation of cancer cell
heterogeneity is kataegis, in which rapid mutations accumulate in
‘‘hotspots’’ to drive the generation of subclones of cancer cells
[1,2]. Although mutations in tumor suppressor genes such as
TP53 are unequivocally involved in many HNSCC, they do not
necessarily define the idiosyncratic genetic features of an
individual tumor. In fact, we noted that the missense mutations
were comparable between patient tumors with or without TP53
mutations. It is likely specific rarer mutational events in a subset
of genes that shape the biologic features of an individual tumor,
such as capability of forming subclones. These subclones may
contribute to divergent responses to adjuvant treatments. It is
possible that specific anatomical sites may have a propensity to
develop tumors with mutations in a specific set of genes.
Compared to keratinized mucosa lining the gingiva, buccal
mucosa, and hard palate, mucosa lining the floor of mouth is
non-keratinized, which makes this site more prone to environ-
mental insults. Our findings that a group of genes pivotal in
modulating host-environment insults interactions were frequently
mutated in HNSCC arising in the floor of mouth suggest their
functional significance in cancer development. Indeed, we found
that mutations in NLRP genes were closely associated with higher
degree of cancer genome instability. The small number of
primary FOM HNSCC analyzed in this study is a limitation.
However, the 62 tumors analyzed represented the common
anatomic sites of primary HNSCC. In addition, we employed
mutations of the TP53 gene and the TLR gene family as
specificity controls. Of the genes analyzed, the association with
FOM was unique to the mutations of the NLRP genes.
In agreement with previous studies [33,34], we found HPV
status and tumor stage were associated with HNSCC patients
overall survival. Although genome instability exemplified by
kataegis represents a defining step in driving the diversity of
tumor subclones, it did not appear to be a reliable prognostic
factor. For example, while HPV negative HNSCC patients had a
significantly elevated level of general mutation rate, advanced
stage tumors did not necessarily display worse genome instability
(Figure S1). However, increased intra-tumor heterogeneity result-
ing from non-driver mutations in a kataegis event may substan-
tially affect the tumor adaptation to treatment, including evolving
resistance to therapy [40]. Hence, the rarer mutations especially
those reflecting genome instability may not be stochastic, rather
they may be the result of a collective response to PAMP/DAMP
Figure 3. Mutation rates of FOM HNSCC. (A) Numbers of missense and nonsense mutations were compared between patients with FOM or non-
FOM HNSCC. (B) Mutation rates were compared between patients with FOM or non-FOM HNSCC.
doi:10.1371/journal.pone.0085619.g003
Identification of NLRP Genes Mutations in HNSCC
PLOS ONE | www.plosone.org 6 January 2014 | Volume 9 | Issue 1 | e85619
challenge and adaptive response to therapeutic inflictions,
contributing to the establishment of resistance.
In Conclusion, We Further Characterized The Genetic And
Clinicopathologic Profile Of The Novel Pyrin-Containing Nlr
Gene Family In 62 Patients With Conventional Type Hnscc.
Clinically, These Mutations Were Frequently Found In Hnscc
Arising In The Floor Of Mouth. These Mutations Were
Clustered At The Lrr Domain Of Nlrp Proteins; And The
Affected Nlrp Genes Were Mostly Localized At Chromosomes
11p15.4 And 19q13.42-19q13.43. Mutations In The Nlrp Genes
Were Associated With Enhanced Genome Instability In Hnscc.
Materials and Methods
Ethics statement
All clinical data including patients’ demographic information,
tumor histologic type and grading, genetic mutation identity,
adjuvant treatment information, and vital status were made
available through the Specialized Program of Research Excellence
(SPORE) in Head and Neck Cancer neoplasm of the University of
Figure 4. Determination of factors affecting overall survival. Patients overall survival analyses were made between two groups: (A) patients
with or without mutations in NLRP genes; (B) patients with or without mutations in TP53 genes; (C) patients with tumors that harbored TLR mutations
and those without TLR mutations; (D) patients with or without HPV infections; (E) patients with low stage (stage II) or advanced stage (stage III and
beyond) tumors; (F) patients of less or more than 56 years old; (G) patients who received no adjuvant therapy, radiotherapy alone or both
chemotherapy and radiotherapy.
doi:10.1371/journal.pone.0085619.g004
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Pittsburgh. Patients included in this study were enrolled into the
Head and Neck tumor bank protocol. This protocol requires
written consent and was approved by the Institutional Review
Board of the University of Pittsburgh.
Study subjects
Whole exome sequencing was performed on 62 patients with
primary or recurrent HNSCC as previously described [6]. Only
patients with primary conventional type squamous cell carcinoma
were included. Recurrent tumors or other histologic variants, such
as basaloid squamous cell carcinoma, papillary squamous cell
carcinoma, spindle cell carcinoma, adenosquamous cell carcino-
ma, and hybrid verrucous squamous cell carcinoma, were
excluded. All participating patients were Caucasians, and other
demographic information was summarized in Table 2.
Data Deposition
Identified mutations associated with our recent whole exome
sequencing effort were made available in dbGaP with the
accession # phs000370.v1.p1 as previously described [6]. All
novel mutations were also available through the COSMIC
database. In order to differentiate the novel mutations associated
with tumors analyzed in this study and those that had been present
in the COSMIC database, we highlighted all novel mutations with
a black triangle in Figure 1.
Gene family coding region calculations
The numbers of amino acids of each member of the TLR or
NLRP families were retrieved from the National Center for
Biotechnology Information (NCBI) protein database, and the
lengths of the coding regions were determined by the number of
the amino acids multiplied by three. The comparison was
analyzed by Mann-Whitney U test, and a P value of less than
0.05 was considered significant.
Statistical Analyses
Comparisons of mutation rates and average ages between the
two groups were made by Mann-Whitney U test. Fisher’s exact
test was employed to analyze contingency tables. Survival
distributions were analyzed by Log Rank test. Analyses were
made using Graphpad Prism 5.0 (Graphpad Software, Inc.). P
value of less than 0.1 was considered to be significant.
Supporting Information
Figure S1 Mutation rates comparisons. (A) Numbers of
missense and nonsense mutations were compared between patients
with or without HPV infection. (B) Mutation rates were compared
between patients with or without HPV infection. (C) Numbers of
missense and nonsense mutations were compared between patients
with low stage or advanced stage SCC. (D) Mutation rates were
compared between patients with low stage or advanced stage
SCC. P value less than 0.05 was considered significant.
(TIF)
Figure S2 Coding region lengths comparisons. (A) The
coding region lengths between selected members of the TLR and
NLRP gene families, which were mutated in our cohort, were
compared by Mann-Whitney U test. (B) The coding region lengths
between the total members of the TLR and NLRP gene families
were compared by Mann-Whitney U test. P value of less than 0.05
was considered significant.
(TIF)
Table S1 Mutations of the TP53 gene were not enriched
in FOM HNSCC. Contingency table comparisons were made by
Fisher’s Exact test to investigate whether mutations of the TP53
gene were more frequently seen in HNSCC arising FOM. P value
of less than 0.1 was considered significant.
(DOCX)
Table S2 Mutations of the TLR genes were not enriched
in FOM HNSCC. Contingency table comparisons were made by
Fisher’s Exact test to investigate whether mutations of the TLR
gene family were more frequently seen in HNSCC arising FOM. P
value of less than 0.1 was considered significant.
(DOCX)
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